MacroGenics, Inc.

Good afternoon. We will begin the Macrogenet 2022 Second Quarter Corporate Progress and Financial Results Conference call in just a moment. All participants in the listen-only mode at the moment, and we will conduct a question-and-answer session at the conclusion of the call. At this point, I will turn the call over to Chris James, Vice President of Investor Relations and Corporate Communications of Macrogenet.

Thank you, Operator. Good afternoon and welcome to Macrogenics' conference call to discuss our second quarter 2022 financial and operational results. For anyone who has not had the chance to review these results, we issued a press release this afternoon outlining today's announcements, which is available under the Investors tab on our website at Macrogenics.com. You may also listen to this conference call via webcast on our website. We will be archived for 30 days beginning approximately two hours after the call is completed. I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans, and prospects that constitute forward-looking statements for purposes of the State Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated for these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of our annual quarterly and current reports filed with the SEC. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change, except to the extent required by applicable law. And now, I'd like to turn the call over to Dr. Scott Koenig, President and Chief Executive Officer of Macrogenics.

Thank you, Chris. I'd like to welcome everyone participating via conference call and webcast today. This afternoon, I will provide key updates on our clinical programs as well as our restructuring plan intended to extend our cash runway. But before I do so, let me first turn the call to Jim Carrolls, our Chief Financial Officer, who will review our financial results.